Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says
The FDA is allowing Regenxbio to resubmit its gene therapy for Hunter syndrome, marking a reversal of a previous rejection.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Regenxbio has been granted a path to resubmit its gene therapy, known as NAVSUNLI, for the treatment of Hunter syndrome (MPS II). This follows a previous rejection by the FDA regarding the childhood treatment.
Coverage from the Wall Street Journal, Endpoints News, Stat News, Stock Titan, and Seeking Alpha highlights the regulatory shift. Reports emphasize that this marks a broader trend of the FDA reconsidering previous decisions for rare-disease drugs.
Regenxbio is expected to move forward with the resubmission process for the drug. Market observers note that the company faces heightened pressure to deliver results regarding its wider pipeline, including ongoing work in Duchenne muscular dystrophy.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 2h ago.
Quick answers
What is the status of the Hunter syndrome gene therapy?
The FDA has granted Regenxbio permission to resubmit its application for NAVSUNLI following a prior rejection.
Which condition is the therapy intended to treat?
The therapy is intended for Hunter syndrome, also referred to as MPS II.
What other conditions is Regenxbio researching?
Coverage indicates the company is also working on treatments for Duchenne muscular dystrophy.
Coverage (8)
- In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy Fierce Biotech · 3h ago
- Reuters US Domestic News Summary Devdiscourse · 3h ago
- US FDA Reverses Course on Regenxbio's Rare-Disease Gene Therapy, Backs Accelerated Approval Bid U.S. News & World Report · 3h ago
- Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues Endpoints News · 3h ago
- REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II Stock Titan · 3h ago
- REGENXBIO’s Duchenne Data Keeps Me Bullish, But There’s Less Room For Setbacks Now (RGNX) Seeking Alpha · 3h ago
- FDA reverses course on Regenxbio’s childhood gene therapy after rejection statnews.com · 3h ago
- Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says WSJ · 3h ago
Topics
Related trends
Trump admin seeks to roll back testosterone restrictions
The Trump administration is pursuing a policy shift to remove or update regulatory restrictions and warning labels on testosterone replacement therapy.
Key FDA committee unanimously recommends its first vaccine since 2023
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
FDA advisors unanimously vote to approve Moderna’s mRNA after agency drama
An FDA advisory committee has unanimously recommended the approval of Moderna's mRNA influenza vaccine for older adults.
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
An FDA advisory committee has unanimously backed Moderna's mRNA-based flu vaccine, marking a significant development for the technology.
"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
The Surprising FDA View That Sent Moderna Stock Flying
Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.